Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy.
Journal of endocrinological investigation 2012 Jul 35 (7): 7.
Xu CW, Wu XB, Ma XL, Wang YS, Zhang BC, Zhao JJ, Wang ZJ, Chen J
- Page last reviewed:Mar 1, 2018
- Page last updated:Jun 13, 2019
- Content source: